Document is current
Any future updates will be listed below
-
Authors
Ozawa, Hiroki
Kawakubo, Hirofumi
Takeuchi, Masashi
Ishibashi, Yoshiki
Matsuda, Satoru
Mayanagi, Shuhei
Takemura, Ryo
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Wada, Norihito
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 14 August 2020
Accepted: 14 December 2020
First Online: 21 March 2021
Disclosure
: Kazumasa Fukuda belongs to the Keio University School of Medicine Endowed Chair in Cancer Research (funded by Chugai Pharmaceutical Co., Ltd and Taiho Pharmaceutical Co., Ltd). Yuko Kitagawa has relevant financial activities outside the submitted work with the following companies: Taiho Pharmaceutical Co., Ltd; Chugai Pharmaceutical Co., Ltd; Yakult Honsha Co. Ltd; Daiichi Sankyo Company, Ltd; Merck Serono Co., Ltd; AsahiKasei Co., Ltd; EA Pharma Co., Ltd; Otsuka Pharmaceutical Co., Ltd; Takeda Pharmaceutical Co., Ltd; Otsuka Pharmaceutical Factory Inc.; Shionogi & Co., Ltd; Kaken Pharmaceutical Co., Ltd; Kowa Pharmaceutical Co., Ltd; Astellas Pharma Inc.; Medicon Inc.; Dainippon Sumitomo Pharma Co., Ltd; Taisho Toyama Pharmaceutical Co., Ltd; Kyouwa Hakkou Kirin Co., Ltd; Pfizer Japan Inc.; Ono Pharmaceutical Co., Ltd; Nihon Pharmaceutical Co., Ltd; Japan Blood Products Organization; Medtronic Japan Co., Ltd; and Sanofi K.K. He has also received grants from Eisai Co., Ltd; Tsumura & Co.; KCI Licensing, Inc.; Abbott Japan Co., Ltd; Fujifilm Toyama Chemical Co., Ltd; and Medicon Inc. Hiroki Ozawa, Hirofumi Kawakubo, Masashi Takeuchi, Yoshiki Ishibashi, Satoru Matsuda, Shuhei Mayanagi, Ryo Takemura, Tomoyuki Irino, Rieko Nakamura, and Norihito Wada have no disclosures to declare.
